Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions

Next Previous
Trial Profile

Phase II Open Label Trial of Thermal Ablation and Lyso-Thermosensitive Liposomal Doxorubicin (Thermodox) for Metastatic Colorectal Cancer (mCRC) Liver Lesions

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 17 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Doxorubicin liposomal (Primary)
  • Indications Colorectal cancer; Liver metastases
  • Focus Therapeutic Use
  • Acronyms ABLATE
  • Sponsors Imunon

Most Recent Events

  • 19 Sep 2022 According to an Imunon media release, Celsion Corporation changed it's name to Imunon.
  • 01 Jun 2013 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
  • 26 Feb 2013 Planned number of patients changed from 88 to 41 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top